ImmunOs Therapeutics AG, a Schlieren (Zurich Area), Switzerland-based biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, raised $74 million in Series B financing.
Click here to read the press release
Target – ImmunOs Therapeutics AG
Buyer – Samsara BioCapital
Buyer – Lightspeed Venture Partners
Buyer – GIMV NV
Buyer – Mission BioCapital
Buyer – GL Capital
Buyer – PEAK6 Investments LLC
Buyer – Fiscus SA
Buyer – Pfizer Ventures LLC
Buyer – BioMedPartners AG
Buyer – Schroder Investment Management (Switzerland) AG
Seller – Shareholders
